两合一抗体同时向EGFR和PD-L1的关联性和瘤细胞结合的平衡
Julia Harwardt1, Felix Klaus Geyer1, Katrin Schoenfeld1
1Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Peter-Grünberg-Strasse 4, 64287 Darmstadt, Germany.
Antibodies (Basel, Switzerland)
|May 28, 2024
概括
我们通过修改单个氨基酸来增强对EGFR的抗体亲和力,提高药物的有效性并降低成本. 这种方法促进了针对性治疗的双特异抗体的开发.
科学领域:
- 生物技术是生物技术.
- 免疫学 免疫学 免疫学
- 药物开发 药物开发
背景情况:
- 单克隆抗体的亲和力对药物的疗效,剂量,安全性和成本至关重要.
- 优化抗体结合可以提高治疗潜力和患者的治疗结果.
研究的目的:
- 为了进行针对EGFR.的双特异EGFR×PD-L1抗体的亲和力成熟.
- 为了提高抗体的结合亲和力,用于增强治疗应用.
主要方法:
- 利用位点定向突变发生和酵母表面显示用于抗体工程.
- 采用生物层干扰测量 (BLI),实时抗原结合试验和流细胞测量用于表征.
- 应用AlphaFold建模来预测结构变化和结合机制.
主要成果:
- 在轻链CDR3.3中通过单个氨基酸替代 (tyrosine to glutamic acid) 实现了EGFR结合亲和力的60倍增加.
- 使用多种生物物理和细胞分析证实了增强的结合特性.
- 阿尔法折叠模型建议盐桥形成,有助于改善亲和力.
结论:
- 开发了一种有效的策略,用于针对一个抗原的双特异抗体的亲和力成熟.
- 单氨基酸交换显著提高了抗体的有效性,并且在抗体工程中具有广泛的应用.
- 这种方法为优化候选药物提供了一条途径,可能降低治疗成本并改善患者治疗.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
290
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
